 PARP inhibitors have been shown to act both by inhibition of PARP enzymatic activity and by "trapping" PARP to DNA at sites of single strand breaks creating lesions that induce cytotoxicity during DNA replication.  We hypothesized that a potent PARP inhibitor like BMN 673 could be a highly effective cytotoxic agent when combined with low doses of TMZ.  The role of TMZ in the combination is to create DNA adducts (via N7, N3, and O6 methylation) that lead to single strand breaks during base excision repair and that in the presence of BMN 673 are converted to cytotoxic lesions.  An in vitro prediction of this hypothesis is that the presence of BMN 673 will markedly reduce the concentration of TMZ required for cytotoxicity (see below).  An in vivo prediction of the hypothesis is that BMN 673 will be highly effective when combined with low doses of TMZ (see far right).
 BMN 673 markedly potentiates the activity of TMZ in vitro, with potentiation being particularly notable for Ewing sarcoma xenografts with the level of potentiation exceeding 50-fold for some cell lines.
 Highly synergistic activity for the BMN 673 + low-dose TMZ combination was observed for 5 of 10 Ewing sarcoma models, with maintained CRs noted in vivo at TMZ doses of 12 mg/kg (~20% of the standard TMZ preclinical dose).
 The BMN 673 + low-dose TMZ combination was also highly active in a MGMTnegative GBM xenograft and in a Wilms tumor xenograft that was responsive to 28 days of single agent BMN 673.
 Additional xenografts are being tested to define the range of activity for the BMN 673 + low-dose TMZ regimen.
 Based on the PPTP results a pediatric phase 1 trial attempting to translate to the clinic the BMN 673 plus low-dose TMZ strategy is planned. • Each line represents the growth of a single tumor.
• For each xenograft line, 10 mice bearing SC tumors initiated treatment when the tumors were between 0.2-0.5 cm3.
•  Maintained CRs were observed both for the regimen with higher dose TMZ and the regimen with low-dose TMZ, and in general responses to the two schedules were comparable. SK-NEP-1 responded better to the low-dose TMZ regimen, while CHLA-258 responded better to the higher-dose TMZ regimen.
 For the MGMT negative glioblastoma xenograft GBM2, both BMN 673 + TMZ combinations induced CRs that were maintained at 6 weeks, and both were more active than TMZ as a single agent at 30 mg/kg/d.  For the Wilms tumor xenograft KT-10 that was highly responsive to single agent BMN 673 (28 day schedule), both combination regimens induced CRs that were maintained through 12 weeks and both were superior to single agent BMN 673 (5 day schedule).  See Figure Legend at upper right for explanation of treatments.
